OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo

OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

A former biopharma firm that developed cannabinoid-based pain medicines.

OCTHF | IL

Overview

Corporate Details

ISIN(s):
GB00BMVMRB86
LEI:
2138005SRWT4998BCE35
Country:
United Kingdom
Address:
PRAMA HOUSE, 267 BANBURY ROAD, OX2 7HT OXFORD

Description

Oxford Cannabinoid Technologies Holdings PLC was a biopharmaceutical company engaged in the research, development, and commercialization of cannabinoid-based prescription medicines. The company's primary focus was on the pain market, with the goal of developing non-addictive medications to reduce reliance on opioids. Its drug discovery programs targeted the endocannabinoid system (ECS) and included a portfolio of proprietary cannabinoid derivatives, in-licensed compounds, and new chemical entities. According to its website, the company ceased trading and entered administration in May 2025.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-08-26 08:00
Strategic Budget Review & Directorate Change
English 16.0 KB
2022-08-15 08:00
Inaugural Meeting of Scientific Advisory Board
English 17.4 KB
2022-08-04 17:03
Annual Report for the period ended 30 April 2022
English 3.6 MB
2022-08-04 08:00
Filing of 2022 Annual Report & Accounts
English 16.7 KB
2022-08-03 12:05
Second Price Monitoring Extn
English 2.8 KB
2022-08-03 12:00
Price Monitoring Extension
English 2.8 KB
2022-07-25 08:00
2022 Final Results
English 646.1 KB
2022-07-20 08:00
Notice of Results
English 14.6 KB
2022-07-20 08:00
MSA and Work Order with Simbec Research
English 16.3 KB
2022-06-29 08:00
Trading Update
English 16.2 KB
2022-05-30 17:40
Second Price Monitoring Extn
English 2.8 KB
2022-05-30 17:35
Price Monitoring Extension
English 2.8 KB
2022-05-16 08:00
New Broker and Investor Presentation
English 11.9 KB
2022-04-25 08:00
Formation of Scientific Advisory Board
English 16.3 KB
2022-04-06 13:58
Results of Requisitioned General Meeting
English 31.2 KB

Automate Your Workflow. Get a real-time feed of all OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.